The U.S. Food and Drug Administration (FDA) has granted approval for ANKTIVA, a novel immunotherapy, in combination with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) that has not responded to BCG therapy. This milestone marks a significant advancement in the fight against NMIBC, a form of bladder cancer that can lead to debilitating consequences if not properly managed.
ANKTIVA’s unique mechanism of action mimics dendritic cell biology, activating both killer and helper T cells. This comprehensive approach enhances the immune system’s ability to proliferate and eliminate cancer cells, resulting in durable complete responses. Unlike checkpoint inhibitors, ANKTIVA targets multiple immune cell types, including NK cells, CD8+ killer T cells, and CD4+ T helper cells.
Clinical trials have demonstrated ANKTIVA’s efficacy, with a 62% complete response rate observed in patients with NMIBC. Notably, the duration of complete response exceeds 47 months, a significant milestone that surpasses the benchmark for meaningful clinical outcomes established by experts in the field.
The long-term benefits of ANKTIVA have the potential to reduce the need for cystectomy, a major surgical procedure that involves the removal of the bladder. Roger Buckley of the IBCG notes that ANKTIVA’s performance “exceeds the clinically meaningful benchmarks established in 2016 for durable complete response.”
ImmunotherapyBio’s dedication to developing cancer vaccines extends beyond ANKTIVA. The company aims to create preventative vaccines for individuals predisposed to cancer, such as those with Lynch syndrome. These advancements underscore ImmunityBio‘s commitment to revolutionizing cancer treatment and improving the quality of life for patients worldwide.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
